LDL Cancer Research Results

LDL, LDL-cholesterol: Click to Expand ⟱
Source:
Type:
The relationship between LDL (low-density lipoprotein) cholesterol and cancer is a complex and evolving area of research. LDL cholesterol is often referred to as "bad" cholesterol because high levels are associated with an increased risk of cardiovascular diseases.

Protumorigenic: High levels of LDL cholesterol can promote tumor growth by providing lipids that are essential for cell membrane synthesis and energy production. Additionally, LDL can influence inflammation and angiogenesis, further supporting tumor development.
Antitumorigenic: Some studies suggest that lowering LDL cholesterol through lifestyle changes or medications (like statins) may have a protective effect against certain cancers, although the evidence is not uniform across all cancer types.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7104- GEN,    Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial
- Trial, Pca, NA
Dose↝, PSA↓, *LDL↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

PSA↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

PSA↓, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: LDL, LDL-cholesterol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:71  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page